Edgell ET - Search Results

1

Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France.

de Zelicourt M, Dardennes R, Verdoux H, Gandhi G, Khoshnood B, Chomette E, Papatheodorou ML, Edgell ET, Even C, Fagnani F. de Zelicourt M, et al. Among authors: edgell et. Pharmacoeconomics. 2003;21(15):1081-90. doi: 10.2165/00019053-200321150-00002. Pharmacoeconomics. 2003. PMID: 14596627

2

[Bipolar I disorder in France: prevalence of manic episodes and hospitalisation-related costs].

de Zélicourt M, Dardennes R, Verdoux H, Gandhi G, Papatheodorou ML, Edgell ET, Khoshnood B, Chomette E, Even C, Fagnani F. de Zélicourt M, et al. Among authors: edgell et. Encephale. 2003 May-Jun;29(3 Pt 1):248-53. Encephale. 2003. PMID: 12876549 Review. French.

3

Costs of bipolar disorder.

Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Kleinman L, et al. Pharmacoeconomics. 2003;21(9):601-22. doi: 10.2165/00019053-200321090-00001. Pharmacoeconomics. 2003. PMID: 12807364 Review.

4

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET. Pike C, et al. Among authors: edgell et. Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000. Pharmacoeconomics. 2010. PMID: 20402541

5

Initial treatment choice in depression: impact on medical expenditures.

Edgell ET, Hylan TR, Draugalis JR, Coons SJ. Edgell ET, et al. Pharmacoeconomics. 2000 Apr;17(4):371-82. doi: 10.2165/00019053-200017040-00007. Pharmacoeconomics. 2000. PMID: 10947492

6

Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.

Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Shi L, et al. Among authors: edgell et. Int Clin Psychopharmacol. 2002 Sep;17(5):227-37. doi: 10.1097/00004850-200209000-00003. Int Clin Psychopharmacol. 2002. PMID: 12177585 Clinical Trial.

7

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Edgell ET, et al. Pharmacoeconomics. 2000 Dec;18(6):567-79. doi: 10.2165/00019053-200018060-00004. Pharmacoeconomics. 2000. PMID: 11227395 Clinical Trial.

8

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Hamilton SH, et al. Among authors: edgell et. Pharmacoeconomics. 1999 May;15(5):469-80. doi: 10.2165/00019053-199915050-00005. Pharmacoeconomics. 1999. PMID: 10537964 Clinical Trial.

9

Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes Study.

Urdahl H, Knapp M, Edgell ET, Ghandi G, Haro JM; SOHO Study Group. Urdahl H, et al. Among authors: edgell et. Acta Psychiatr Scand Suppl. 2003;(416):41-7. doi: 10.1034/j.1600-0447.107.s416.2.x. Acta Psychiatr Scand Suppl. 2003. PMID: 12755853

10

Sertraline. A pharmacoeconomic evaluation of its use in depression.

Edgell ET, Hylan TR, Sacristán JA. Edgell ET, et al. Pharmacoeconomics. 1997 Apr;11(4):377-80. doi: 10.2165/00019053-199711040-00009. Pharmacoeconomics. 1997. PMID: 10184683 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters